News

Press Releases

September 8, 2025
OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer

PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy […]

Read more
August 18, 2025
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer

ROCKVILLE, Maryland, August 18, 2025 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today […]

Read more
July 28, 2025
OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease

SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia […]

Read more
July 22, 2025
OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US

Excellent safety observed across initial dose escalation with objective response at the lowest dose tested (1 mg/kg of AI-081) ROCKVILLE, […]

Read more
July 15, 2025
OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies

Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ROCKVILLE, Maryland, […]

Read more
Scroll to Top